Skip to content

Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery

Impact of Tight Control of Perioperative Blood Glucose in Patients Undergoing Vascular Surgery on Their Perioperative Cardiovascular and Overall Morbidity and Mortality

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00328094
Enrollment
242
Registered
2006-05-19
Start date
2006-03-31
Completion date
2009-05-31
Last updated
2013-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Aortic Aneurysm, Peripheral Vascular Disease

Keywords

Tight, Glycemic, control, outcomes, peripheral vascular disease, infection, cardiovascular, morbidity, mortality

Brief summary

Aggressive intraoperative and postoperative management of blood glucose may substantially decrease perioperative cardiovascular and infectious complications in diabetic and non-diabetic patients undergoing vascular surgery. The purpose of this study is to compare the tight versus traditional blood glucose control in diabetics and non-diabetics undergoing vascular surgery in regard to their postoperative fatal and nonfatal cardiac outcomes, and the secondary effects such as rate of infections, overall morbidity and 30-day mortality.

Detailed description

This is a randomized, prospective controlled trial in both diabetic and non diabetic patients undergoing vascular surgery such as abdominal aortic, infra inguinal vascular bypass procedures and amputations, comparing tight versus standard blood glucose control regimens in the operating room, post anesthesia care unit and in the postoperative vascular intensive care unit up to 48 hours and its impact on the cardiovascular, infectious and other morbidity and mortality during the hospital admission and up to 30 days from surgery. After obtaining informed consent, the study subjects will be randomized to tight versus standard blood glucose control regimens. These regimens will be started in the operating room and continued for the first 48 hours or until their discharge, whichever is earlier. All the patients will be inpatients. Day surgery patients will be excluded. The anesthesiologist providing patient care will be given either the tight glucose control protocol or the standard sliding scale insulin protocol. In the tight control regimen, target blood glucose is 100-150 mg/dl. If 3 consecutive blood glucose (BG) level \>150 mg/dL or 1 BG level \>200 mg/dL, then the insulin infusion will be initiated in the tight control group. The insulin infusion rate adjustments will be made based on the blood sugar results. In post anesthetic care unit (PACU) and vascular intensive care unit (VICU), these protocols will be nurse driven. The adjustments will be made based on the current blood sugar levels as well as the insulin infusion rates. They are adjusted in such a way to account for the rate of change of blood sugars and the presence of steroid therapy in the patients. The frequency of blood glucose testing in this group will be every 1-hour until stable (when frequent changes in insulin dosage are no longer necessary, and glucose is in the range of 100 to 150 for 3 consecutive blood sugar checks); then test every 2 hours for 3 consecutive target values and then every 4 hours thereafter. If there is a change in the infusion rates, then blood sugar checks will be done every hour and the cycle followed thereafter. In the standard sliding scale insulin group, blood sugars will be treated with insulin boluses if the blood sugars go more than 150 mg/dL and blood glucose will be monitored every 4 hours. These regimens will be initiated after 2 weeks of in-service training for anesthesiologists, post anesthetic care unit (PACU) and vascular intensive care unit (VICU) nurses. The study investigators will provide this training. Insulin infusion in the tight control regimen will be started through pump piggyback to maintenance intravenous infusion as follows. Insulin infusion bags will be made by the pharmacy (100 units in a 100 ml bag). The anesthesiologists in the operating room and PACU, and VICU nurses will perform blood glucose monitoring, bolus insulin administration, and infusion initiation and rate adjustments as specified by the protocol. Blood glucose levels will be tested by finger stick method or arterial line drop sample.

Interventions

DRUGcontinuous intravenous insulin infusion

Tight glucose control versus standard of care

Sponsors

Beth Israel Deaconess Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Abdominal aortic surgery * Supra and infrainguinal peripheral vascular bypass surgery * Below knee amputations * Above knee amputations * Diabetics and nondiabetics * American Society of Anesthesiologists (ASA) I-III

Exclusion criteria

* Brittle diabetics * ASA 1V,V * Second surgery in same admission

Design outcomes

Primary

MeasureTime frame
Composite (Myocardial Infarction and CHF)hospital length of stay

Secondary

MeasureTime frame
Incidence of Wound Infectionspostoperative

Countries

United States

Participant flow

Recruitment details

Perioperative period in Beth Israel Deaconess Medical Center, West Campus was the only location for the recruitment.

Pre-assignment details

252 were assessed for eligibility. 10 did not meet inclusion criterion.

Participants by arm

ArmCount
Continuous Insulin Infusion
Tight glucose group with insulin infusion
114
Intermittent Insulin Bolus
Intermittent insulin boluses group
122
Total236

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyPhysician Decision33

Baseline characteristics

CharacteristicIntermittent Insulin BolusContinuous Insulin InfusionTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
79 Participants65 Participants144 Participants
Age, Categorical
Between 18 and 65 years
43 Participants49 Participants92 Participants
Age Continuous71 years
STANDARD_DEVIATION 11
67 years
STANDARD_DEVIATION 10
69 years
STANDARD_DEVIATION 11
Region of Enrollment
United States
122 participants114 participants236 participants
Sex: Female, Male
Female
56 Participants47 Participants103 Participants
Sex: Female, Male
Male
66 Participants67 Participants133 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
23 / 11422 / 122
serious
Total, serious adverse events
10 / 1145 / 122

Outcome results

Primary

Composite (Myocardial Infarction and CHF)

Time frame: hospital length of stay

ArmMeasureValue (NUMBER)
Continuous Insulin InfusionComposite (Myocardial Infarction and CHF)4 Number of patients
Intermittent Insulin BolusComposite (Myocardial Infarction and CHF)15 Number of patients
Secondary

Incidence of Wound Infections

Time frame: postoperative

ArmMeasureValue (NUMBER)
Continuous Insulin InfusionIncidence of Wound Infections35 participants
Intermittent Insulin BolusIncidence of Wound Infections29 participants
p-value: 0.2395% CI: [0.85, 1.97]Chi-squared

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026